Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2580812 | 0.98 | ESRRG (0.43) | PTGIRESRRGHTR7KDM4EBRAF | |
| SCHEMBL1385611 | 0.93 | PTGIR (0.44) | PTGIRHTR7KDM4EBRAFMAPK3 | |
| Hydrochloric Acid SCHEMBL2579363 | 0.91 | PTGIR (0.43) | PTGIRESRRGHTR7KDM4EBRAF | |
| SCHEMBL2578488 | 0.90 | BRAF (0.39) | PTGIRESRRGHTR7BRAFMAPK3 | |
| Hydrochloric Acid SCHEMBL2581759 | 0.89 | BRAF (0.39) | PTGIRESRRGHTR7BRAFMAPK3 | |
| SCHEMBL2581616 | 0.85 | BRAF (0.39) | ESRRGHTR7BRAFMAPK3MAPK1 | |
| SCHEMBL1386220 | 0.85 | POLB (0.44) | PTGIRKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL2581718 | 0.84 | CSNK1D (0.38) | ESRRGHTR7BRAFMAPK3MAPK1 | |
| Hydrochloric Acid SCHEMBL2577845 | 0.84 | POLB (0.43) | PTGIRKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL1384048 | 0.84 | KDM5B (0.40) | PTGIRKDM4EALDH1A1SMN1; SMN2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4833078-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| CN-102174017-A | Pyrazolyl derivatives in the form of drugs for treating acute or chronic neuronal regressions | AVENTIS PHARMA SA | 2011-09-07 | — | — | CN | claimed |
| US-7524838-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2009-04-28 | — | — | US | claimed |
| EP-1689720-B1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2009-04-15 | — | — | EP | claimed |
| CN-1906172-A | Pyrazole derivatives as medicaments for the treatment of acute or chronic neuronal degeneration | AVENTIS PHARMA SA (FR) | 2007-01-31 | — | — | CN | claimed |
| EP-1689720-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | Aventis Pharma S.A. (FR) | 2006-08-16 | — | — | EP | claimed |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | claimed |
| WO-2005051917-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA S.A. (FR) | 2005-06-09 | — | — | WO | claimed |
| US-8048893-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA SA (FR) | 2011-11-01 | — | — | US | disclosed |
| CN-102174017-A | Pyrazolyl derivatives in the form of drugs for treating acute or chronic neuronal regressions | AVENTIS PHARMA SA | 2011-09-07 | — | — | CN | disclosed |
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2009-07-02 | — | — | US | disclosed |
| US-7524838-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2009-04-28 | — | — | US | disclosed |
| EP-1689720-B1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2009-04-15 | — | — | EP | disclosed |
| CN-1906172-A | Pyrazole derivatives as medicaments for the treatment of acute or chronic neuronal degeneration | AVENTIS PHARMA SA (FR) | 2007-01-31 | — | — | CN | disclosed |
| EP-1689720-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | Aventis Pharma S.A. (FR) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051917-A9 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2005-09-29 | — | — | WO | disclosed |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | disclosed |
| WO-2005051917-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA S.A. (FR) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | C1R, CBR3, C3AR1 | PTGIR 1522/4885ESRRG 919/4885HTR7 58/4885 |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | C1R, CBR3, C3AR1 | PTGIR 1532/4885ESRRG 935/4885HTR7 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.